Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Ogalvibart, an antibody targeting SARS-CoV-2 Spike RBD.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Luveltamab, an antibody targeting Folate receptor alpha.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Lomtegovimab, an antibody targeting SARS-CoV-2 Spike RBD.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Livmoniplimab, an antibody targeting LRRC32.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Crexavibart, an antibody targeting SARS-CoV-2 Spike RBD.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Adintrevimab, an antibody targeting SARS-CoV-2 Spike.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Ulviprubart, an antibody targeting KLRG1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Simaravibart, an antibody targeting SARS-CoV-2 Spike RBD.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Sabirnetug, an antibody targeting Amyloid-beta.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Raludotatug, an antibody targeting CDH6.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Vecantoxatug, an antibody targeting Clostridium tetani tetanus toxin (TeNT).

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Tizetatug, an antibody targeting TROP2.